DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
van der Hiel B, Haanen JBAG, Stokkel MPM. et al.
Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: Response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): Study protocol of a phase II, open-label, multicenter study.
BMC Cancer 2017;
17: 649
We do not assume any responsibility for the contents of the web pages of other providers.